These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 28081540)

  • 1. Efficacy of fluoropyrimidine-based chemotherapy in patients with advanced biliary tract cancer after failure of gemcitabine plus cisplatin: retrospective analysis of 321 patients.
    Kim BJ; Yoo C; Kim KP; Hyung J; Park SJ; Ryoo BY; Chang HM
    Br J Cancer; 2017 Feb; 116(5):561-567. PubMed ID: 28081540
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison between Fluoropyrimidine-Cisplatin and Gemcitabine-Cisplatin as First-Line Chemotherapy for Advanced Biliary Tract Cancer: A Meta-Analysis.
    Zheng T; Jin J; Zhou L; Zhang Y
    Oncol Res Treat; 2020; 43(9):460-469. PubMed ID: 32629449
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gemcitabine-based versus fluoropyrimidine-based chemotherapy with or without platinum in unresectable biliary tract cancer: a retrospective study.
    Kim MJ; Oh DY; Lee SH; Kim DW; Im SA; Kim TY; Heo DS; Bang YJ
    BMC Cancer; 2008 Dec; 8():374. PubMed ID: 19091129
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of FOLFIRINOX Chemotherapy with Other Regimens in Patients with Biliary Tract Cancers: a Retrospective Study.
    Kus T; Aktas G; Kalender ME; Sevinc A; Camci C
    J Gastrointest Cancer; 2017 Jun; 48(2):170-175. PubMed ID: 27714651
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of a sequential treatment strategy with GEMOX-based followed by FOLFIRI-based chemotherapy in advanced biliary tract cancers.
    Sebbagh S; Roux J; Dreyer C; Neuzillet C; de Gramont A; Orbegoso C; Hentic O; Hammel P; de Gramont A; Raymond E; André T; Chibaudel B; Faivre S
    Acta Oncol; 2016; 55(9-10):1168-1174. PubMed ID: 27333436
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Second-line chemotherapy for advanced biliary tract cancer after failure of the gemcitabine-platinum combination: A large multicenter study by the Association des Gastro-Entérologues Oncologues.
    Brieau B; Dahan L; De Rycke Y; Boussaha T; Vasseur P; Tougeron D; Lecomte T; Coriat R; Bachet JB; Claudez P; Zaanan A; Soibinet P; Desrame J; Thirot-Bidault A; Trouilloud I; Mary F; Marthey L; Taieb J; Cacheux W; Lièvre A
    Cancer; 2015 Sep; 121(18):3290-7. PubMed ID: 26052689
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial.
    Hegewisch-Becker S; Graeven U; Lerchenmüller CA; Killing B; Depenbusch R; Steffens CC; Al-Batran SE; Lange T; Dietrich G; Stoehlmacher J; Tannapfel A; Reinacher-Schick A; Quidde J; Trarbach T; Hinke A; Schmoll HJ; Arnold D
    Lancet Oncol; 2015 Oct; 16(13):1355-69. PubMed ID: 26361971
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI) as a third-line chemotherapy treatment in metastatic gastric cancer, after failure of fluoropyrimidine, platinum, anthracycline, and taxane.
    Erdem GU; Bozkaya Y; Ozdemir NY; Demirci NS; Yazici O; Zengin N
    Bosn J Basic Med Sci; 2018 May; 18(2):170-177. PubMed ID: 28941466
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase 2 study of copanlisib in combination with gemcitabine and cisplatin in advanced biliary tract cancers.
    Tan ES; Cao B; Kim J; Al-Toubah TE; Mehta R; Centeno BA; Kim RD
    Cancer; 2021 Apr; 127(8):1293-1300. PubMed ID: 33289918
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The efficacy of fluoropyrimidine-based adjuvant chemotherapy on biliary tract cancer after R0 resection.
    Kim YS; Jeong CY; Song HN; Kim TH; Kim HJ; Lee YJ; Hong SC
    Chin J Cancer; 2017 Jan; 36(1):9. PubMed ID: 28086990
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Benefit of Maintenance Therapy for Advanced Biliary Tract Cancer Patients Showing No Progression after First-Line Gemcitabine Plus Cisplatin.
    Hyung J; Kim B; Yoo C; Kim KP; Jeong JH; Chang HM; Ryoo BY
    Cancer Res Treat; 2019 Jul; 51(3):901-909. PubMed ID: 30282446
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Capecitabine plus cisplatin as first-line chemotherapy for advanced biliary tract cancer: a retrospective single-center study.
    Woo SM; Lee WJ; Han SS; Park SJ; Kim TH; Koh YH; Kim HB; Hong EK; Park JW; Kim CM
    Chemotherapy; 2012; 58(3):225-32. PubMed ID: 22831988
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is there a role for second-line platinum re-challenge in advanced biliary tract cancers?
    Adhikaree J; Madhusudan S
    Med Oncol; 2014 Jul; 31(7):46. PubMed ID: 24913810
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination Therapy with Capecitabine and Cisplatin as Second-Line Chemotherapy for Advanced Biliary Tract Cancer.
    Jung JH; Lee HS; Jo JH; Cho IR; Chung MJ; Bang S; Park SW; Song SY; Park JY
    Chemotherapy; 2017; 62(6):361-366. PubMed ID: 28848173
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gemcitabine plus cisplatin versus capecitabine plus cisplatin as first-line chemotherapy for advanced biliary tract cancer: a retrospective cohort study.
    Woo SM; Lee WJ; Kim JH; Kim DH; Han SS; Park SJ; Kim TH; Lee JH; Koh YH; Hong EK
    Chemotherapy; 2013; 59(3):232-8. PubMed ID: 24356333
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of modified FOLFIRINOX as salvage therapy for patients with refractory advanced biliary tract cancer: a retrospective study.
    Ye LF; Ren C; Bai L; Liang JY; Hu MT; Yang H; Wang ZQ; Wang FH; Xu RH; Li YH; Wang DS
    Invest New Drugs; 2021 Jun; 39(3):836-845. PubMed ID: 33411209
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment outcomes of gemcitabine alone versus gemcitabine plus platinum for advanced biliary tract cancer: a Korean Cancer Study Group retrospective analysis.
    Hwang IG; Song HS; Lee MA; Nam EM; Lim J; Lee KH; Lee KT; Zang DY; Jang JS
    Cancer Chemother Pharmacol; 2014 Dec; 74(6):1291-6. PubMed ID: 25326056
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic factors in patients with advanced biliary tract cancer treated with first-line gemcitabine plus cisplatin: retrospective analysis of 740 patients.
    Kim BJ; Hyung J; Yoo C; Kim KP; Park SJ; Lee SS; Park DH; Song TJ; Seo DW; Lee SK; Kim MH; Park JH; Cho H; Ryoo BY; Chang HM
    Cancer Chemother Pharmacol; 2017 Jul; 80(1):209-215. PubMed ID: 28597043
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of gemcitabine plus cisplatin versus capecitabine plus cisplatin as first-line chemotherapy for advanced biliary tract cancer.
    Park K; Kim KP; Park S; Chang HM
    Asia Pac J Clin Oncol; 2017 Feb; 13(1):13-20. PubMed ID: 27770489
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination versus mono-therapy as salvage treatment for advanced biliary tract cancer: A comprehensive meta-analysis of published data.
    Ying J; Chen J
    Crit Rev Oncol Hematol; 2019 Jul; 139():134-142. PubMed ID: 30979533
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.